A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Caffeine (Primary) ; Capmatinib (Primary) ; Midazolam (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis
- 21 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
- 11 Jul 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.